AZTREONAM injection, powder, lyophilized, for solution

Aztreonam by

Drug Labeling and Warnings

Aztreonam by is a Prescription medication manufactured, distributed, or labeled by Hospira, Inc., Hospira Australia Pty Ltd, Curia Italy S.r.l.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Concurrent Therapy

Concurrent initial therapy with other antimicrobial agents and aztreonam for injection is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to Gram-positive aerobic pathogens. If anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with aztreonam for injection (see DOSAGE AND ADMINISTRATION). Certain antibiotics (eg, cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some Gram-negative aerobes such as Enterobacter and Pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. These in vitro findings suggest that such beta-lactamase inducing antibiotics not be used concurrently with aztreonam. Following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued.

  • CONTRAINDICATIONS

    This preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

  • WARNINGS

    Both animal and human data suggest that aztreonam for injection is rarely cross-reactive with other beta-lactam antibiotics and weakly immunogenic. Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure (see CONTRAINDICATIONS).

    Careful inquiry should be made to determine whether the patient has any history of hypersensitivity reactions to any allergens.

    While cross-reactivity of aztreonam with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams (eg, penicillins, cephalosporins, and/or carbapenems). Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure to aztreonam. If an allergic reaction to aztreonam occurs, discontinue the drug and institute supportive treatment as appropriate (eg, maintenance of ventilation, pressor amines, antihistamines, corticosteroids). Serious hypersensitivity reactions may require epinephrine and other emergency measures (see ADVERSE REACTIONS).

    Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including aztreonam for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    Rare cases of toxic epidermal necrolysis have been reported in association with aztreonam in patients undergoing bone marrow transplant with multiple risk factors including sepsis, radiation therapy, and other concomitantly administered drugs associated with toxic epidermal necrolysis.

  • PRECAUTIONS

    General

    Prescribing aztreonam in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.

    If an aminoglycoside is used concurrently with aztreonam, especially if high dosages of the former are used or if therapy is prolonged, renal function should be monitored because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics.

    The use of antibiotics may promote the overgrowth of nonsusceptible organisms, including Gram-positive organisms (Staphylococcus aureus and Streptococcus faecalis) and fungi. Should superinfection occur during therapy, appropriate measures should be taken.

    Information for Patients

    Patients should be counseled that antibacterial drugs including aztreonam should only be used to treat bacterial infections. They do not treat viral infections (eg, the common cold). When aztreonam is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by aztreonam or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity studies with aztreonam have not been conducted using an intravenous route of administration. A 104-week rat inhalation toxicology study to assess the carcinogenic potential of aztreonam demonstrated no drug-related increase in the incidence of tumors. Rats were exposed to aerosolized aztreonam for up to 4 hours per day. Peak plasma levels of aztreonam averaging approximately 6.8 mcg/mL were measured in rats at the highest dose level.

    Genetic toxicology studies performed with aztreonam in vitro (Ames test, mouse lymphoma forward mutation assay, gene conversion assay, chromosome aberration assay in human lymphocytes) and in vivo (mouse bone marrow cytogenetic assay) did not reveal evidence of mutagenic or clastogenic potential.

    A two-generation reproduction study in rats at daily doses of 150, 600, or 2,400 mg/kg given prior to and during gestation and lactation, revealed no evidence of impaired fertility. Based on body surface area, the high dose is 2.9-fold greater than the maximum recommended human dose (MRHD) for adults of 8 g per day. There was a slightly reduced survival rate during the lactation period in the offspring of rats that received the highest dose, but not in offspring of rats that received lower doses of aztreonam.

    Pregnancy

    In pregnant women, aztreonam crosses the placenta and enters the fetal circulation.

    Developmental toxicity studies in pregnant rats and rabbits with daily doses of aztreonam up to 1,800 and 1,200 mg/kg, respectively, revealed no evidence of embryotoxicity or fetotoxicity or teratogenicity. These doses, based on body surface area, are 2.2- and 2.9-fold greater than the MRHD for adults of 8 g per day. A peri/postnatal study in rats revealed no drug-induced changes in any maternal, fetal, or neonatal parameters. The highest dose used in this study, 1,800 mg/kg/day, is 2.2 times the MRHD based on body surface area.

    There are no adequate and well-controlled studies of aztreonam on human pregnancy outcomes. Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.

    Nursing Mothers

    Aztreonam is excreted in human milk in concentrations that are less than 1% of concentrations determined in simultaneously obtained maternal serum; consideration should be given to temporary discontinuation of nursing and use of formula feedings.

    Pediatric Use

    The safety and effectiveness of intravenous aztreonam for injection have been established in the age groups 9 months to 16 years. Use of aztreonam for injection in these age groups is supported by evidence from adequate and well-controlled studies of aztreonam for injection in adults with additional efficacy, safety, and pharmacokinetic data from non-comparative clinical studies in pediatric patients. Sufficient data are not available for pediatric patients under 9 months of age or for the following treatment indications/pathogens: septicemia and skin and skin-structure infections (where the skin infection is believed or known to be due to H. influenzae type b). In pediatric patients with cystic fibrosis, higher doses of aztreonam for injection may be warranted (see CLINICAL PHARMACOLOGY, DOSAGE AND ADMINISTRATION, and CLINICAL STUDIES).

    Geriatric Use

    Clinical studies of aztreonam for injection did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    In elderly patients, the mean serum half-life of aztreonam increased and the renal clearance decreased, consistent with the age-related decrease in creatinine clearance. Since aztreonam is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, renal function should be monitored and dosage adjustments made accordingly (see DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients and Dosage in the Elderly).

    Aztreonam for Injection contains no sodium.

  • ADVERSE REACTIONS

    Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively.

    Systemic reactions (considered to be related to therapy or of uncertain etiology) occurring at an incidence of 1% to 1.3% include diarrhea, nausea and/or vomiting, and rash. Reactions occurring at an incidence of less than 1% are listed within each body system in order of decreasing severity:

    Hypersensitivity—anaphylaxis, angioedema, bronchospasm

    Hematologic—pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis

    Gastrointestinal—abdominal cramps; rare cases of C. difficile–associated diarrhea, including pseudomembranous colitis, or gastrointestinal bleeding have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

    Dermatologic—toxic epidermal necrolysis (see WARNINGS), purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis

    Cardiovascular—hypotension, transient ECG changes (ventricular bigeminy and PVC), flushing

    Respiratory—wheezing, dyspnea, chest pain

    Hepatobiliary—hepatitis, jaundice

    Nervous System—seizure, confusion, encephalopathy, vertigo, paresthesia, insomnia, dizziness

    Musculoskeletal—muscular aches

    Special Senses—tinnitus, diplopia, mouth ulcer, altered taste, numb tongue, sneezing, nasal congestion, halitosis

    Other—vaginal candidiasis, vaginitis, breast tenderness

    Body as a Whole—weakness, headache, fever, malaise

    Pediatric Adverse Reactions

    Of the 612 pediatric patients who were treated with aztreonam for injection in clinical trials, less than 1% required discontinuation of therapy due to adverse events. The following systemic adverse events, regardless of drug relationship, occurred in at least 1% of treated patients in domestic clinical trials: rash (4.3%), diarrhea (1.4%), and fever (1.0%). These adverse events were comparable to those observed in adult clinical trials.

    In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%). In the US patient population, pain occurred in 1.5% of patients, while each of the remaining 3 local reactions had an incidence of 0.5%.

    The following laboratory adverse events, regardless of drug relationship, occurred in at least 1% of treated patients: increased eosinophils (6.3%), increased platelets (3.6%), neutropenia (3.2%), increased AST (3.8%), increased ALT (6.5%), and increased serum creatinine (5.8%).

    In US pediatric clinical trials, neutropenia (absolute neutrophil count less than 1,000/mm3) occurred in 11.3% of patients (8/71) younger than 2 years receiving 30 mg/kg every 6 hours. AST and ALT elevations to greater than 3 times the upper limit of normal were noted in 15% to 20% of patients aged 2 years or above receiving 50 mg/kg every 6 hours. The increased frequency of these reported laboratory adverse events may be due to either increased severity of illness treated or higher doses of aztreonam for injection administered.

    Adverse Laboratory Changes

    Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:

    Hepatic—elevations of AST (SGOT), ALT (SGPT), and alkaline phosphatase; signs or symptoms of hepatobiliary dysfunction occurred in less than 1% of recipients (see above).

    Hematologic—increases in prothrombin and partial thromboplastin times, positive Coombs' test.

    Renal—increases in serum creatinine.

  • OVERDOSAGE

    If necessary, aztreonam may be cleared from the serum by hemodialysis and/or peritoneal dialysis.

  • DOSAGE AND ADMINISTRATION

    Dosage in Adult Patients

    Aztreonam for Injection may be administered intravenously or by intramuscular injection. Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient.

    Table 2: Aztreonam for Injection Dosage Guidelines for Adults*
    Type of InfectionDoseFrequency
    (hours)
  • * Maximum recommended dose is 8 g per day.
    		•

    Urinary tract infections

    500 mg or 1 g

    8 or 12

    Moderately severe systemic infections

    1 g or 2 g

    8 or 12

    Severe systemic or life-threatening infections

    2 g

    6 or 8

    Because of the serious nature of infections due to Pseudomonas aeruginosa, dosage of 2 g every six or eight hours is recommended, at least upon initiation of therapy, in systemic infections caused by this organism.

    The intravenous route is recommended for patients requiring single doses greater than 1 g or those with bacterial septicemia, localized parenchymal abscess (eg, intra-abdominal abscess), peritonitis, or other severe systemic or life-threatening infections.

    The duration of therapy depends on the severity of infection. Generally, aztreonam for injection should be continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. Persistent infections may require treatment for several weeks. Doses smaller than those indicated should not be used.

    Renal Impairment in Adult Patients

    Prolonged serum levels of aztreonam may occur in patients with transient or persistent renal insufficiency. Therefore, the dosage of aztreonam for injection should be halved in patients with estimated creatinine clearances between 10 and 30 mL/min/1.73 m2 after an initial loading dose of 1 g or 2 g.

    When only the serum creatinine concentration is available, the following formula (based on sex, weight, and age of the patient) may be used to approximate the creatinine clearance (Clcr). The serum creatinine should represent a steady-state of renal function.

        Males: Clcr =      weight (kg) × (140−age)      
                               72 × serum creatinine (mg/dL)
        Females:   0.85 × above value

    In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m2), such as those supported by hemodialysis, the usual dose of 500 mg, 1 g, or 2 g should be given initially. The maintenance dose should be one-fourth of the usual initial dose given at the usual fixed interval of 6, 8, or 12 hours. For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session.

    Dosage in the Elderly

    Renal status is a major determinant of dosage in the elderly; these patients in particular may have diminished renal function. Serum creatinine may not be an accurate determinant of renal status. Therefore, as with all antibiotics eliminated by the kidneys, estimates of creatinine clearance should be obtained and appropriate dosage modifications made if necessary.

    Dosage in Pediatric Patients

    Aztreonam for Injection should be administered intravenously to pediatric patients with normal renal function. There are insufficient data regarding intramuscular administration to pediatric patients or dosing in pediatric patients with renal impairment (see PRECAUTIONS: Pediatric Use).

    Table 3: Aztreonam for Injection Dosage Guidelines for Pediatric Patients*
    Type of InfectionDoseFrequency
    (hours)
  • * Maximum recommended dose is 120 mg/kg/day.
    		•

    Mild to moderate infections

    30 mg/kg

    8

    Moderate to severe infections

    30 mg/kg

    6 or 8
  • CLINICAL STUDIES

    A total of 612 pediatric patients aged 1 month to 12 years were enrolled in uncontrolled clinical trials of aztreonam in the treatment of serious Gram-negative infections, including urinary tract, lower respiratory tract, skin and skin-structure, and intra-abdominal infections.

    Preparation of Parenteral Solutions

    General

    Upon the addition of the diluent to the container, contents should be shaken immediately and vigorously. Use constituted solution immediately. Discard any remaining unused constituted solution.

    Depending upon the concentration of aztreonam and diluent used, constituted aztreonam for injection yields a colorless to light straw yellow solution which may develop a slight pink tint on standing (potency is not affected). Parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit.

    Admixtures with Other Antibiotics

    Intravenous infusion solutions of aztreonam for injection not exceeding 2% w/v prepared with Sodium Chloride Injection, USP 0.9% or Dextrose Injection, USP 5%, to which clindamycin phosphate, gentamicin sulfate, tobramycin sulfate, or cefazolin sodium have been added at concentrations usually used clinically, are stable for up to 48 hours at controlled room temperature 15°C to 30°C (59°F to 86°F) or 7 days under refrigeration 2°C to 8°C (36°F to 46°F). Ampicillin sodium admixtures with aztreonam in Sodium Chloride Injection, USP 0.9% are stable for 24 hours at controlled room temperature 15°C to 30°C (59°F to 86°F) and 48 hours under refrigeration 2°C to 8°C (36°F to 46°F); stability in Dextrose Injection, USP 5% is 2 hours at controlled room temperature 15°C to 30°C (59°F to 86°F) and 8 hours under refrigeration 2°C to 8°C (36°F to 46°F).

    Aztreonam-cloxacillin sodium and aztreonam-vancomycin hydrochloride admixtures are stable in Dianeal 137 (Peritoneal Dialysis Solution) with 4.25% Dextrose for up to 24 hours at controlled room temperature 15°C to 30°C (59°F to 86°F).

    Aztreonam is incompatible with nafcillin sodium, cephradine, and metronidazole.

    Other admixtures are not recommended since compatibility data are not available.

    Intravenous Solutions

    For Bolus Injection

    The vial contents should be constituted with 6 mL to 10 mL Sterile Water for Injection, USP.

    For Infusion

    If the vial contents are to be transferred to an appropriate infusion solution, each gram of aztreonam should be initially constituted with at least 3 mL Sterile Water for Injection, USP. Further dilution may be obtained with one of the following intravenous infusion solutions:

    •   Sodium Chloride Injection, USP, 0.9%
    •   Ringer's Injection, USP
    •   Lactated Ringer's Injection, USP
    •   Dextrose Injection, USP, 5% or 10%
    •   Dextrose and Sodium Chloride Injection, USP, 5%:0.9%, 5%:0.45%, or 5%:0.2%
    •   Sodium Lactate Injection, USP (M/6 Sodium Lactate)
    •   Ionosol® B and 5% Dextrose
    •   Isolyte® M with 5% Dextrose
    •   Normosol®-R
    •   Normosol®-R and 5% Dextrose
    •   Normosol®-M and 5% Dextrose
    •   Mannitol Injection, USP, 5% or 10%
    •   Lactated Ringer's and 5% Dextrose Injection

    Intramuscular Solutions

    The vial contents should be constituted with at least 3 mL of an appropriate diluent per gram aztreonam. The following diluents may be used:

    •   Sterile Water for Injection, USP
    •   Sterile Bacteriostatic Water for Injection, USP (with benzyl alcohol or with methyl- and propylparabens)
    •   Sodium Chloride Injection, USP, 0.9%
    •   Bacteriostatic Sodium Chloride Injection, USP (with benzyl alcohol)

    Stability of Intravenous and Intramuscular Solutions

    Aztreonam for Injection solutions for intravenous infusion at concentrations not exceeding 2% w/v must be used within 48 hours following constitution if kept at controlled room temperature 15°C to 30°C (59°F to 86°F) or within 7 days if refrigerated 2°C to 8°C (36°F to 46°F).

    Aztreonam for Injection solutions at concentrations exceeding 2% w/v, except those prepared with Sterile Water for Injection, USP or Sodium Chloride Injection, USP, should be used promptly after preparation; the 2 excepted solutions must be used within 48 hours if stored at controlled room temperature 15°C to 30°C (59°F to 86°F) or within 7 days if refrigerated 2°C to 8°C (36°F to 46°F).

    Intravenous Administration

    Bolus Injection

    A bolus injection may be used to initiate therapy. The dose should be slowly injected directly into a vein, or the tubing of a suitable administration set, over a period of 3 to 5 minutes (see next paragraph regarding flushing of tubing).

    Infusion

    With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously. Any aztreonam infusion should be completed within a 20- to 60-minute period. With use of a Y-type administration set, careful attention should be given to the calculated volume of aztreonam solution required so that the entire dose will be infused. A volume control administration set may be used to deliver an initial dilution of aztreonam for injection (see Preparation of Parenteral Solutions: Intravenous Solutions: For Infusion) into a compatible infusion solution during administration; in this case, the final dilution of aztreonam should provide a concentration not exceeding 2% w/v.

    Intramuscular Administration

    The dose should be given by deep injection into a large muscle mass (such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh). Aztreonam is well tolerated and should not be admixed with any local anesthetic agent.

  • HOW SUPPLIED

    Aztreonam for Injection, USP single-dose vials are supplied as follows:

    Unit of SaleStrengthEach

    NDC: 0409-0829-01
    Carton containing 10

    1 gram/vial

    NDC: 0409-0829-11
    Single-dose vial

    NDC: 0409-0830-01
    Carton containing 10

    2 grams/vial

    NDC: 0409-0830-11
    Single-dose vial

    Storage

    Store in original package at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature]; avoid excessive heat.

  • SPL UNCLASSIFIED SECTION

    Distributed by
    Hospira, Inc.
    Lake Forest, IL 60045 USA

    Logo

    LAB-0806-2.0

    Revised: 6/2024

  • PRINCIPAL DISPLAY PANEL - 1 gram Vial Label

    NDC: 0409-0829-11
    Rx Only

    Aztreonam for
    Injection, USP
    1 gram/vial

    For Intravenous or Intramuscular use after constitution.

    PRINCIPAL DISPLAY PANEL - 1 gram Vial Label
  • PRINCIPAL DISPLAY PANEL - 1 gram Vial Carton

    10 x 1 gram Single-Dose Vials

    NDC: 0409-0829-01
    Contains 10 of NDC: 0409-0829-11

    Aztreonam
    for Injection, USP
    1 gram/vial

    For Intravenous or Intramuscular use after constitution.

    Rx only

    Hospira

    PRINCIPAL DISPLAY PANEL - 1 gram Vial Carton
  • PRINCIPAL DISPLAY PANEL - 2 gram Vial Label

    NDC: 0409-0830-11

    Aztreonam
    for Injection, USP
    2 grams/vial

    For Intravenous or Intramuscular
    use after constitution.

    Rx Only

    Hospira

    PRINCIPAL DISPLAY PANEL - 2 gram Vial Label
  • PRINCIPAL DISPLAY PANEL - 2 gram Vial Carton

    10 x 2 grams Single-Dose Vials

    NDC: 0409-0830-01
    Contains 10 of NDC: 0409-0830-11

    Aztreonam
    for Injection, USP
    2 grams/vial

    For Intravenous or Intramuscular use after constitution.

    Rx only

    Hospira

    PRINCIPAL DISPLAY PANEL - 2 gram Vial Carton
  • INGREDIENTS AND APPEARANCE
    AZTREONAM 
    aztreonam injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0409-0829
    Route of AdministrationINTRAVENOUS, INTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    AZTREONAM (UNII: G2B4VE5GH8) (AZTREONAM - UNII:G2B4VE5GH8) AZTREONAM1 g
    Inactive Ingredients
    Ingredient NameStrength
    ARGININE (UNII: 94ZLA3W45F) 780 mg
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0409-0829-0110 in 1 CARTON01/24/2022
    1NDC: 0409-0829-111 in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20651701/24/2022
    AZTREONAM 
    aztreonam injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0409-0830
    Route of AdministrationINTRAVENOUS, INTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    AZTREONAM (UNII: G2B4VE5GH8) (AZTREONAM - UNII:G2B4VE5GH8) AZTREONAM2 g
    Inactive Ingredients
    Ingredient NameStrength
    ARGININE (UNII: 94ZLA3W45F) 1.56 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0409-0830-0110 in 1 CARTON01/24/2022
    1NDC: 0409-0830-111 in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20651701/24/2022
    Labeler - Hospira, Inc. (141588017)
    Establishment
    NameAddressID/FEIBusiness Operations
    Hospira Australia Pty Ltd758967652ANALYSIS(0409-0829, 0409-0830) , MANUFACTURE(0409-0829, 0409-0830) , PACK(0409-0829, 0409-0830) , LABEL(0409-0829, 0409-0830)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.